PF-08046876 for people with advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

PF-08046876 is an investigational antibody–drug conjugate that targets integrin beta‑6 and delivers a cytotoxic payload to cancer cells. This Phase 1, open-label study enrolls adults with advanced or metastatic solid tumors, including urothelial (bladder) and non–small cell lung cancers, to receive intravenous infusions of the study drug. The protocol uses dose-escalation cohorts and may test multiple dosing schedules to define safety, tolerability, and preliminary anti-tumor activity, and requires available pre-treatment tumor tissue when medically feasible. Early parts require prior progression after standard therapies while a later part limits prior systemic therapy in the advanced setting to two lines.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years of age or older
* Advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas
* Measurable disease
* ECOG Performance status 0-1
* Part 1: progression or relapse following standard treatments
* Part 2: maximum of 2 prior lines of systemic therapy in the advanced setting
* Part 3: advanced cancer of the lung or bladder, prior treatment requirements vary by combination therapy group
* Resolution of acute effects of prior anticancer therapy to baseline or Grade 1
* Consent to submit required pre-treatment tumor tissue as medically feasible

Exclusion criteria:

* Received prior treatment with an antibody drug conjugate with a camptothecin-class payload (e.g. sacituzumab govitecan, trastuzumab deruxtecan )
* Active anorexia, nausea or vomiting, and/or signs of intestinal obstruction meeting protocol exclusion
* Pulmonary disease meeting protocol exclusion
* Other unacceptable abnormalities as defined by protocol
* Part 3: Meet contraindications of combination products per protocol and/or local labels

Where it's running

• City of Hope National Medical Center
  Duarte, California, United States Recruiting
• City of Hope at Irvine Lennar
  Irvine, California, United States Recruiting
• Administrative Address: UCLA Hematology/Oncology
  Los Angeles, California, United States Recruiting
• Ronald Reagan UCLA Medical Center
  Los Angeles, California, United States Recruiting
• Santa Monica UCLA Medical Center & Orthopaedic Hospital
  Santa Monica, California, United States Recruiting
• UCLA Hematology/Oncology - Santa Monica
  Santa Monica, California, United States Recruiting

Study contacts

• Study coordinator: Pfizer CT.gov Call Center
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Phone: 1-800-718-1021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• Testing NEO212 for treating certain brain tumors and metastases

  This study is testing a new treatment called NEO212 for people with certain types of brain tumors to see if it is safe and effective when combined with standard treatments.

  Recruiting at 8 sites Phase 1/2 Neonc Technologies, Inc. · Beverly Hills, California and 7 other locations · NCT06047379

• Validation of a blood test for early cancer detection and monitoring

  This study is testing a blood test to see if it can help find different types of cancer early and monitor patients after treatment.

  Recruiting at 3 sites Adela, Inc · Duarte, California and 16 other locations · NCT05366881

• Using stereotactic body radiotherapy for patients with rare oligometastatic cancers

  This study is testing if adding a special type of targeted radiation therapy to standard treatment can help people with rare cancers that have spread to a few places live longer and feel better.

  Recruiting at 13 sites European Organisation for Research and Treatment of Cancer - EORTC · Anderlecht and 12 other locations · NCT04498767

• Testing a new drug for advanced solid tumors

  This study is testing a new drug called sigvotatug vedotin to see if it can safely help people with advanced solid tumors, both on its own and with other treatments.

  Recruiting at 145 sites Phase 1 Seagen Inc. · Anchorage, Alaska and 157 other locations · NCT04389632

• Evaluating the impact of MR-guided radiation therapy on cancer treatment outcomes

  This study is testing how using a special type of radiation therapy with real-time imaging can improve treatment results and quality of life for adults with cancer.

  Recruiting at 14 sites UMC Utrecht · Pittsburgh, Pennsylvania and 17 other locations · NCT04075305

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.